scholarly journals Characterization of an associated microfibril protein through recombinant DNA techniques.

1992 ◽  
Vol 267 (14) ◽  
pp. 10087-10095
Author(s):  
S.K. Horrigan ◽  
C.B. Rich ◽  
B.W. Streeten ◽  
Z.Y. Li ◽  
J.A. Foster
Blood ◽  
1989 ◽  
Vol 73 (2) ◽  
pp. 490-496 ◽  
Author(s):  
PM George ◽  
P Pemberton ◽  
IC Bathurst ◽  
RW Carrell ◽  
HL Gibson ◽  
...  

Abstract Both congenital and acquired antithrombin-III (AT-III) deficiencies are amenable to replacement therapy. We describe two antithrombins produced by recombinant DNA techniques from human alpha 1-antitrypsin (alpha 1AT) cDNA in yeast. Alteration of the alpha 1AT active site, replacing methionine 358 with arginine, results in a thrombin inhibition rate similar to that of heparin-activated AT-III. Alteration of two further residues, to give a five-residue sequence identical to AT-III, does not increase this rate further. Neither antithrombin is activated by heparin; both are unglycosylated and have shorter in vivo half-lives (t1/2) than human alpha 1AT. These antithrombins should be suitable for therapeutic replacement of AT-III in cases of congenital deficiency and in conditions associated with acquired AT-III deficiency, such as disseminated intravascular coagulation.


1987 ◽  
Vol 247 (3) ◽  
pp. 785-788 ◽  
Author(s):  
R M L Jones ◽  
K Rose ◽  
R E Offord

Biosynthetic human proinsulin (obtained by recombinant DNA techniques) was used as the starting material for the preparation, by semisynthetic methods, of [3H]proinsulin with the label at the N-terminal phenylalanine residue. The labelled proinsulin was characterized by its retention time on reversed-phase h.p.l.c., by polyacrylamide-gel electrophoresis, by the time course of its enzymic conversion into insulin and by chromatographic analysis after extensive proteolytic degradation. The specific radioactivity of the product was 5 Ci/mmol. Experimental details of the preparation of human [[3H]Phe1]proinsulin, the isolation of this product by isocratic h.p.l.c. and gel filtration, and further characterization of protein intermediates have been deposited as supplement SUP 50138 (12 pages) at the British Library Lending Division, Boston Spa, Wetherby, West Yorkshire LS23 7BQ, U.K., from whom copies can be obtained on prepayment [see Biochem. J. (1987) 241, 5].


Blood ◽  
1989 ◽  
Vol 73 (2) ◽  
pp. 490-496
Author(s):  
PM George ◽  
P Pemberton ◽  
IC Bathurst ◽  
RW Carrell ◽  
HL Gibson ◽  
...  

Both congenital and acquired antithrombin-III (AT-III) deficiencies are amenable to replacement therapy. We describe two antithrombins produced by recombinant DNA techniques from human alpha 1-antitrypsin (alpha 1AT) cDNA in yeast. Alteration of the alpha 1AT active site, replacing methionine 358 with arginine, results in a thrombin inhibition rate similar to that of heparin-activated AT-III. Alteration of two further residues, to give a five-residue sequence identical to AT-III, does not increase this rate further. Neither antithrombin is activated by heparin; both are unglycosylated and have shorter in vivo half-lives (t1/2) than human alpha 1AT. These antithrombins should be suitable for therapeutic replacement of AT-III in cases of congenital deficiency and in conditions associated with acquired AT-III deficiency, such as disseminated intravascular coagulation.


Genetics ◽  
1989 ◽  
Vol 122 (2) ◽  
pp. 331-339
Author(s):  
M E Katz ◽  
M J Hynes

Abstract Four Aspergillus nidulans genes are known to be under the control of the trans-acting regulatory gene amdR. We describe the isolation and initial characterization of one of these amdR-regulated genes, lamA. The lam locus, however, was found to consist of two divergently transcribed genes, the lamA gene, and a new gene, also under amdR control, which we have designated lamB. Using recombinant DNA techniques we have constructed a strain of A. nidulans lacking a functional lamB gene. Experiments conducted with this strain demonstrate that lamB, like lamA, is involved in utilization of 2-pyrrolidinone in A. nidulans. Metabolism of a related compound, gamma-amino butyric acid (GABA) is not affected. We also provide evidence that the conversion of exogenous 2-pyrrolidinone to endogenous GABA requires a functional lamB gene. The expression of both lamA and lamB is subject to carbon and nitrogen metabolite repression in addition to amdR-mediated induction by omega-amino acids.


1979 ◽  
Vol 254 (13) ◽  
pp. 6187-6195
Author(s):  
J Robbins ◽  
P Rosteck ◽  
J R Haynes ◽  
G Freyer ◽  
M L Cleary ◽  
...  

1984 ◽  
Vol 37 (1-4) ◽  
pp. 210-273 ◽  
Author(s):  
M.H. Skolnick ◽  
H.F. Willard ◽  
L.A. Menlove

Gene ◽  
1983 ◽  
Vol 26 (2-3) ◽  
pp. 323-324
Author(s):  
A.J. Podhajska

BioEssays ◽  
1984 ◽  
Vol 1 (1) ◽  
pp. 12-15 ◽  
Author(s):  
Stephen Hodgkinson ◽  
Peter Scambler

1985 ◽  
Vol 162 (2) ◽  
pp. 663-674 ◽  
Author(s):  
A Yamada ◽  
M R Ziese ◽  
J F Young ◽  
Y K Yamada ◽  
F A Ennis

We have tested the abilities of various polypeptides of A/PR/8/34 (H1N1) virus, constructed by recombinant DNA techniques, to induce influenza virus-specific secondary cytotoxic T lymphocyte (CTL) responses. A hybrid protein (c13 protein), consisting of the first 81 amino acids of viral nonstructural protein (NS1) and the HA2 subunit of viral hemagglutinin (HA), induced H-2-restricted, influenza virus subtype-specific secondary CTL in vitro, although other peptides did not. Using a recombinant virus, the viral determinant responsible for recognition was mapped to the HA2 portion of c13 protein. Immunization of mice with c13 protein induced the generation of memory CTL in vivo. The CTL precursor frequencies of A/PR/8/34 virus- and c13 protein-immune mice were estimated as one in 8,047 and 50,312, respectively. These results indicate that c13 protein primed recipient mice, even though the level of precursor frequency was below that observed in virus-immune mice.


Sign in / Sign up

Export Citation Format

Share Document